Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Silvercorp to Acquire Adventus Creating a Diversified Mining Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aptevo Therapeutics Inc APVO

Healthcare Biotechnology
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company. It is focused on developing novel immunotherapy candidates for the treatment of different forms of cancer. It has developed two versatile and enabling platform technologies for rational design of precision immune modulatory drugs. Its lead clinical candidates, APVO436 and ALG.APV-527, and preclinical candidates, APVO603 and... see more

Recent & Breaking News (NDAQ:APVO)

Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering

Accesswire 11 days ago

Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering

Accesswire April 11, 2024

Aptevo Therapeutics Provides Pipeline Update

Accesswire April 10, 2024

Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference

Accesswire March 18, 2024

Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4

Accesswire March 7, 2024

Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update

Accesswire March 5, 2024

Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan

Accesswire March 4, 2024

Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update

Accesswire November 14, 2023

Aptevo to Present at Bio-Europe Conference

Accesswire November 1, 2023

Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update

Accesswire August 10, 2023

Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering

Accesswire August 4, 2023

Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering

Accesswire August 1, 2023

Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML

Accesswire July 18, 2023

Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update

Accesswire May 11, 2023

Aptevo Therapeutics Reports 2022 Financial Results and Provides Business Update

Accesswire March 30, 2023

Aptevo Therapeutics Raises $9.6 Million in Non-Dilutive Funding

Accesswire March 30, 2023

Alligator Bioscience & Aptevo Therapeutics Announce Dosing of First Patient with ALG.APV-527 in Phase 1 Clinical Trial

Accesswire February 13, 2023

Aptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid Tumors

Accesswire January 9, 2023

100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)

Accesswire December 12, 2022

Aptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights

Accesswire November 10, 2022